Drugs / PF-07921585
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06580938 | Nov 2024 → Jul 2025 | colorectal cancer, head and neck cancer, melanoma, non-small cell lung carcinoma +2 | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07921585 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06580938 ↗ |
| Modality | Protein / enzyme biologic | “IL-12 mutein” NCT06580938 ↗ |
| Route | Intravenous | “administered once every 3 weeks intravenously or subcutaneously” NCT06580938 ↗ |
| Route | Subcutaneous | “administered once every 3 weeks intravenously or subcutaneously” NCT06580938 ↗ |